VR Logo

Lyra Therapeutics Inc. (LYRA) download report


Healthcare | Biotechnology & Pharma Research

Lyra Therapeutics Inc. (LYRA) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases.

IPO Date: 01-May-2020

CEO, Pres & Director: Dr. Maria Palasis Ph.D.

CFO, Treasurer & Sec.: Mr. Jason Cavalier

Listing: NASDAQ: LYRA

Country: United States

Headquarters: Watertown, MA

Website: https://lyratherapeutics.com

Key Facts

Market cap: $169.95 Mln

Revenue (TTM): $5.64 Mln

Earnings (TTM): $-42.72 Mln

Cash: $33.76 Mln

Total Debt: $1.20 Mln

Insider's Holding: 1.16%

Liquidity: Low

52 Week range: $3.30 - 9.98

Shares outstanding: 31,825,100

Stock Performance

Time Period Lyra Therapeutics (LYRA) S&P BSE Sensex S&P Small-Cap 600
YTD25.23-8.99-19.23
1 month-4.71-3.40-9.35
3 months33.50-8.50-16.59
1 Year-34.690.89-17.36
3 Years--10.415.90
5 Years--11.435.77
10 Years--11.779.78
As on 30-Jun-2022
Year Lyra Therapeutics (LYRA) S&P Small-Cap 600 S&P BSE Sensex
2021-61.7525.2721.99